A study recently published in the Journal of Dermatological Science further examines the pharmacodynamic profile of brimonidine (Mirvaso, Galderma Laboratories). Approved in August 2013, brimonidine is thought to work to reduce facial erythema by vasoconstriction of cutaneous blood vessels by targeting alpha-adrenergic agonists.
Using an ex vivo wire myography and human skin biopsy neuroinflammation model, researchers measured the vasoconstrictive effects of brimonidine. The anti-inflammatory properties of brimonidine were examined using 2 in vivo mice ear inflammation models.
What they found was that brimonidine was highly selective for the alpha-2A adrenergic receptor compared with other adrenoreceptors. The study also showed that brimonidine is a potent vasoconstrictor of human subcutaneous vessels with a diameter of less than 200 μm. The in vivo mouse ear inflammation model found that brimonidine reduced ear edema by up to 76%compared to a placebo agent.
In the treatment of rosacea, the most common adverse events with brimonidine include erythema, flushing, skin burning sensation and contact dermatitis.
Piwnica D, Rosignoll C, De Ménoville T, et al. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci. Published online ahead of print April 16, 2014.
A study recently published in the Journal of Dermatological Science further examines the pharmacodynamic profile of brimonidine (Mirvaso, Galderma Laboratories). Approved in August 2013, brimonidine is thought to work to reduce facial erythema by vasoconstriction of cutaneous blood vessels by targeting alpha-adrenergic agonists.
Using an ex vivo wire myography and human skin biopsy neuroinflammation model, researchers measured the vasoconstrictive effects of brimonidine. The anti-inflammatory properties of brimonidine were examined using 2 in vivo mice ear inflammation models.
What they found was that brimonidine was highly selective for the alpha-2A adrenergic receptor compared with other adrenoreceptors. The study also showed that brimonidine is a potent vasoconstrictor of human subcutaneous vessels with a diameter of less than 200 μm. The in vivo mouse ear inflammation model found that brimonidine reduced ear edema by up to 76%compared to a placebo agent.
In the treatment of rosacea, the most common adverse events with brimonidine include erythema, flushing, skin burning sensation and contact dermatitis.
Piwnica D, Rosignoll C, De Ménoville T, et al. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci. Published online ahead of print April 16, 2014.
A study recently published in the Journal of Dermatological Science further examines the pharmacodynamic profile of brimonidine (Mirvaso, Galderma Laboratories). Approved in August 2013, brimonidine is thought to work to reduce facial erythema by vasoconstriction of cutaneous blood vessels by targeting alpha-adrenergic agonists.
Using an ex vivo wire myography and human skin biopsy neuroinflammation model, researchers measured the vasoconstrictive effects of brimonidine. The anti-inflammatory properties of brimonidine were examined using 2 in vivo mice ear inflammation models.
What they found was that brimonidine was highly selective for the alpha-2A adrenergic receptor compared with other adrenoreceptors. The study also showed that brimonidine is a potent vasoconstrictor of human subcutaneous vessels with a diameter of less than 200 μm. The in vivo mouse ear inflammation model found that brimonidine reduced ear edema by up to 76%compared to a placebo agent.
In the treatment of rosacea, the most common adverse events with brimonidine include erythema, flushing, skin burning sensation and contact dermatitis.
Piwnica D, Rosignoll C, De Ménoville T, et al. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci. Published online ahead of print April 16, 2014.
